Vivani Medical, Inc.
Vivani Medical develops miniature, long-acting subdermal drug implant candidates using its NanoPortal technology, which is designed to deliver medicines at a near-constant rate and can be stopped by removing the implant. The clinical-stage biopharmaceutical company focuses on peptide therapies for chronic diseases, particularly metabolic conditions, with implants intended to improve medication adherence and tolerability. Its programs include semaglutide implants NPM-139 for chronic weight management and NPM-133 for type 2 diabetes, exenatide implant NPM-115 for weight management, and OKV-119 for weight management and diabetes in companion cats and dogs. OKV-119 is being developed with animal health partner Okava Pharmaceuticals. Vivani’s business centers on developing and potentially commercializing its implant candidates, alone or with pharmaceutical partners. The NanoPortal platform uses a titanium-oxide nanoporous membrane and is designed for delivery lasting six months or longer, with implants removable to stop treatment. Vivani also owns Cortigent, a subsidiary holding legacy neurostimulation assets contributed by Second Sight. The company is headquartered in Alameda, California.
No SEC Form 4 filings for $VANI in the last 30 days.
See all $VANI insider activity →Vivani Medical (NASDAQ:VANI) reported Phase 1 trial results for NPM-139, a semaglutide implant for weight management. The trial showed no adverse events in the NPM-139 group, with similar weight loss to Wegovy. Vivani plans to advance to Phase 2 trials in 2027 and explore development in new patient groups. The company collaborates with Novo Nordisk on the technology.
Vivani Medical (VANI) reported a Q3 2026 net loss of $7.3M, up from $6.5M in Q3 2025. Cash reserves declined to $15.5M from $20.8M in Q2 2026. The company awaits SLIM-1 trial results and Cortigent merger completion.
Vivani Medical's merger with Cortigent awaits final regulatory approval, with closing expected shortly after. The deal will make Cortigent a subsidiary of ClearOne. Vivani had initially targeted an October 2026 closing, but the timeline is now uncertain. The transaction may not be completed due to regulatory or other issues, according to the company.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning VANI (Vivani Medical, Inc.). Coverage has skewed bearish: 1 bullish, 1 neutral, and 3 bearish.
Recent VANI coverage spans financial news, earnings and mergers & acquisitions.
Positive early‑stage data may boost investor confidence in Vivani's pipeline.
The results suggest increased financial pressure and may trigger a sell‑off.
The pending approval creates uncertainty, likely weighing on VANI shares until the deal clears.
The pending merger creates uncertainty about future ownership and potential dilution, likely weighing on the stock until approval is received.
The announced merger could affect Vivani's share price and valuation as the transaction terms are clarified.
AlphAI scores every news story that mentions VANI with an AI model for sentiment and relevance, and aggregates insider trades from Vivani Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vivani Medical (NASDAQ:VANI) reported Phase 1 trial results for NPM-139, a semaglutide implant for weight management. The trial showed no adverse events in the NPM-139 group, with similar weight loss to Wegovy. Vivani plans to advance to Phase 2 trials in 2027 and explore development in new patient groups. The company collaborates with Novo Nordisk on the technology.
Vivani Medical (VANI) reported a Q3 2026 net loss of $7.3M, up from $6.5M in Q3 2025. Cash reserves declined to $15.5M from $20.8M in Q2 2026. The company awaits SLIM-1 trial results and Cortigent merger completion.
Vivani Medical's merger with Cortigent awaits final regulatory approval, with closing expected shortly after. The deal will make Cortigent a subsidiary of ClearOne. Vivani had initially targeted an October 2026 closing, but the timeline is now uncertain. The transaction may not be completed due to regulatory or other issues, according to the company.
Vivani Medical, Inc. (VANI) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 . Regulation FD Disclosure. As previously disclosed, Vivani Medical, Inc. (“Vivani”) entered into a definitive agreement and plan of merger among its wholly owned subsidiary Cortigent, Inc. (“Cortigent”), ClearOne, Inc. (“ClearOne”), and CLRO Merger Sub, Inc. (“MergerSu
Vivani Medical, Inc. (VANI) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 . Regulation FD Disclosure. As previously disclosed, Vivani Medical, Inc. (“Vivani”) entered into a definitive agreement and plan of merger among its wholly owned subsidiary Cortigent, Inc. (“Cortigent”), ClearOne, Inc. (“ClearOne”), and CLRO Merger Sub, Inc. (“MergerSu
Vivani Medical, Inc. (VANI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight mana
Williams Gregg purchased 793,650 indirectly-held shares of Vivani Medical, Inc. (VANI) at $1.26 ($1.00M total) on 2026-07-15.
Vivani Medical (NASDAQ: VANI) said it signed an agreement with Novo Nordisk to let Novo evaluate Vivani’s NPM-139 semaglutide implant using Vivani’s NanoPortal platform for chronic weight management. The companies noted no exclusivity. Vivani expects to start a Phase 1 first-in-human trial in mid-2026, comparing with Wegovy, to support a Phase 2 dose-ranging study.
Vivani Medical (NASDAQ: VANI) said it signed an agreement with Novo Nordisk to let Novo evaluate Vivani’s NPM-139 semaglutide implant using Vivani’s NanoPortal platform for chronic weight management. Vivani noted no exclusivity. It plans to start a Phase 1 first-in-human study mid-2026, using Wegovy as comparator, to support a Phase 2 dose-ranging study.
Vivani Medical (Nasdaq: VANI) said it signed a non-exclusive agreement with Novo Nordisk to let Novo evaluate Vivani’s NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management. Vivani expects to start a Phase 1 first-in-human trial of NPM-139 mid-2026, using Wegovy as an active comparator.
